CD274 and head and neck squamous cell carcinoma: Nivolumab plus ipilimumab or the EXTREME regimen were evaluated for cost-effectiveness, as a first-line treatment for R/M SCCHN, in the United States, by all randomly assigned patients, as well as, patients with PD-L1 high expression, based on the results of CheckMate 651.